Cat. No. 4436
Chemical Name: 6-Amino-8-chloropurine riboside
Biological ActivityNucleoside analog; metabolized in vivo to 8-Chloro-ATP. Incorporates into RNA during transcription and inhibits RNA synthesis. Exhibits cytotoxicity in MM.1S, RPMI-8226 and U266 cancer cell lines; induces G2/M cell cycle arrest and mitotic catastrophe in A549 and H1299 cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Cervantes-Gomez et al (2011) ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J.Pharmacol.Exp.Ther. 339 545. PMID: 21821695.
Gu et al (2006) 8-Chloro-adenosine inhibits growth at least partly by interfering with actin polymerization in cultured human lung cancer cells Biochem.Pharmacol. 72 541. PMID: 16844099.
Zhang et al (2004) Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia 6 802. PMID: 15720807.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for 8-Chloroadenosine include:
Kearney et al (2015) 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS One 10 e0135962. PMID: 26313261.
Do you know of a great paper that uses 8-Chloroadenosine from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 8-Chloroadenosine, supplier, 8-Cl-Ado, 8-Cl-ATP, cytotoxic, chemotherapeutics, growth, arrest, RNA, synthesis, transcription, inhibitors, inhibits, nucleoside, analogs, Tocris Bioscience, DNA, RNA and Protein Synthesis Inhibitor products
Find multiple products by catalog number
New Products in this Area
mRNA splicing inhibitor; antitumorLin28 1632
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
April 1 - 5, 2017
Washington, D.C., USA